Cancer Research UK. Breast cancer statistics. 2018. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#heading-Two. Accessed 12 December 2023.

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

Article  PubMed  Google Scholar 

Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, et al. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. Cancer Treat Rev. 2022;111: 102468.

Article  PubMed  Google Scholar 

Anders CK, Zagar TM, Carey LA. Management of early stage and metastatic triple negative breast cancer: a review. Hematol Oncol Clin North Am. 2013;27:737–49.

Article  PubMed  PubMed Central  Google Scholar 

Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer Basic Clin Res. 2016;10:25–36.

Article  Google Scholar 

Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8:1913–24.

Article  PubMed  Google Scholar 

Almansour NM. Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. Front Mol Biosci. 2022;9:1–15.

Article  Google Scholar 

SEER*Explorer: an interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute; 2023 Apr 19 [updated: 2023 Nov 16]. https://seer.cancer.gov/statistics-network/explorer/. Accessed 16 April 2024.

Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107:djv048.

Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381: e071674.

Article  PubMed  Google Scholar 

Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217–26.

Article  PubMed  Google Scholar 

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.

Article  PubMed  Google Scholar 

Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ B. 2015. https://doi.org/10.14694/EdBook_AM.2015.35.e31.

Article  Google Scholar 

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475–95.

Article  PubMed  Google Scholar 

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. TNBC: challenges and opportunities of a heterogenous disease. Nat Rev Clin Oncol. 2016;13:674–90.

Article  PubMed  PubMed Central  Google Scholar 

Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72:165–82.

Article  PubMed  Google Scholar 

EMA. ENHERTU SmPC. 2021. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Accessed 2 January 2025.

Moon S, Govindan SV, Cardillo TM, Christopher A, Souza D, Hansen HJ, et al. Antibody conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med. 2009;51:6916–26.

Google Scholar 

Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2020;11:942.

Article  PubMed  PubMed Central  Google Scholar 

EMA. TRODELVY SmPC. 2021. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf. Accessed 2 January 2025.

Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49:1331–7.

Article  PubMed  Google Scholar 

Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther. 2008;7:2003–11.

Article  PubMed  PubMed Central  Google Scholar 

Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914–23.

Article  PubMed  Google Scholar 

Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148:553–61.

Article  PubMed  PubMed Central  Google Scholar 

O’Shaughnessy J, Punie K, Oliveira M, Lynce F, Tolaney SM, Dalenc F, et al. Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. 2021;39:1077.

Article  Google Scholar 

Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33:594–601.

Article  PubMed  PubMed Central  Google Scholar 

Cigler TJ. Eribulin mesylate in the treatment of metastatic breast cancer. Biol Targets Ther. 2012;6:21–9.

Article  Google Scholar 

Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997;15:1395–400.

Article  PubMed  Google Scholar 

Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol. 1994;12:2094–101.

Article  PubMed  Google Scholar 

emc. Vinorelbine SMPC. https://www.medicines.org.uk/emc/product/311/smpc. Accessed 2 January 2025.

Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat. 2012;133:1067–75.

Article  PubMed  Google Scholar 

Wang J, Zheng R, Wang Z, Yang Y, Wang M, Zou W. Efficacy and safety of vinorelbine plus cisplatin vs. gemcitabine plus cisplatin for treatment of metastatic triple-negative breast cancer after failure with anthracyclines and taxanes. Med Sci Monit. 2017;23:4657–64.

Article  PubMed  PubMed Central  Google Scholar 

Li DD, Tao ZH, Wang BY, Wang LP, Cao J, Hu XC, et al. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial. Breast Cancer. 2022;8:1–8.

Google Scholar 

Gao C, Zhao Z, Liu W, Li Y, Li H, Ma X, et al. Evaluation of clinical efficacy and toxicities of GP or NX regimen in patients with recurrent metastatic triple negative breast cancer. Anti-Tumor Pharm. 2022;12:60–4.

Google Scholar 

Chai Y, Liu J, Jiang M, He M, Wang Z, Ma F, et al. A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer. Thorac Cancer. 2023;14:2259–68.

Article  PubMed  PubMed Central  Google Scholar 

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–51.

Article  PubMed  Google Scholar 

Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:499–511.

Article  PubMed  Google Scholar 

Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8:219–25.

Article  PubMed  Google Scholar 

Im S-A, Cortes J, Lipatov O, Goncalves A, Lee K-S, Schmid P, et al. 44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation. Ann Oncol. 2020;31:S1258.

Article  Google Scholar 

Okines AFC, Irfan T, Mohammed K, Ring A, Parton M, Kipps E, et al. Vinorelbine after prior treatment with eribulin for advanced breast cancer: a single-centre experience suggesting cross-resistance. Clin Breast Cancer. 2022;22:e825–31.